Market Cap (In USD)
69.66 Million
Revenue (In USD)
-
Net Income (In USD)
-16.48 Million
Avg. Volume
495.53 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.078-46.0
- PE
- -
- EPS
- -
- Beta Value
- 0.0
- ISIN
- US31573L1052
- CUSIP
- -
- CIK
- 1958777
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Peter O'Heeron
- Employee Count
- -
- Website
- https://www.fibrobiologics.com
- Ipo Date
- 2024-02-01
- Details
- FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
More Stocks
-
605388
-
1088
-
BNAI
-
IDR
-
TM
-
BOWFF
-
600161
-
STMRF